Dr. T asks:
There is universal agreement that high dose intravenous bisphosphonates for e.g. myeloma or disseminated carcinoma, are an absolute contraindication to dental implants, whereas most US implantologists do not seem overly worried about treating clients on low dose oral bisphosphonates, such as Fosamax 70mg weekly.
However, I am seeing more and more patients who are on monthly, 3-monthly or annual regimes and I would be interested in your views on the wisdom of treating these people with dental implants. None of the various position papers on oral surgery and bisphosphonates seem to tackle these “in between” cases. Any comments?